NCT04319757View on ClinicalTrials.gov

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

July 15, 2024

Study Completion Date

July 15, 2024

Conditions
Locally Advanced Solid TumorMetastatic CancerSolid TumorHER2-positive Gastric CancerHER2-positive Metastatic Breast Cancer
Interventions
DRUG

ACE1702

ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

Trial Locations (3)

60611

Northwestern Univeristy, Chicago

77030

MD Anderson Cancer Center, Houston

Unknown

Taipei Veteran General Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Acepodia Biotech, Inc.

INDUSTRY

NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | Biotech Hunter | Biotech Hunter